Telomir Pharmaceuticals Inc
TELO1.870USD
+0.110+6.25%
Trading geöffnet （ET）Kurse um 15 Minuten verzögert
55.66MMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über Telomir Pharmaceuticals Inc Unternehmen
Telomir Pharmaceuticals, Inc. is a pre-clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of TELOMIR-1, a novel small molecule designed to lengthen the DNA’s protective telomere caps, thereby promoting longevity in humans and canine animals by treating age-related conditions. TELOMIR-1 is undergoing studies to provide a therapeutic intervention against contracting a number of degenerative and age-related diseases. Its Telomir-1, is being investigated for its potential to address a range of conditions, including Type 2 diabetes, Wilson’s disease, progeria, Alzheimer’s disease, and cancer. The Company is focused on developing and commercializing TELOMIR-1, proposed to be dosed orally, with the aim of promoting longevity and enhancing overall quality of life. It is being developed to protect stem cells by elongating and stimulating the telomeres to sustain self-renewal.
Unternehmensinformationen
BörsenkürzelTELO
Name des UnternehmensTelomir Pharmaceuticals Inc
IPO-datumFeb 09, 2024
CEOMr. Erez Aminov
Anzahl der mitarbeiter- -
WertpapierartOrdinary Share
GeschäftsjahresendeFeb 09
Addresse900 West Platt Street, Suite 200
StadtTAMPA
BörseNASDAQ Capital Market Consolidated
LandUnited States of America
Postleitzahl33606
Telefon18138642562
Websitehttps://telomirpharma.com/
BörsenkürzelTELO
IPO-datumFeb 09, 2024
CEOMr. Erez Aminov
Führungskräfte
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Erez Aminov
Mr. Erez Aminov
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
1.01M
+3288.20%
Mr. Craig Eagle, M.D.
Mr. Craig Eagle, M.D.
Independent Director
Independent Director
487.81K
--
Dr. Matthew P. Del Giudice
Dr. Matthew P. Del Giudice
Director
Director
--
--
Mr. Ned Macpherson
Mr. Ned Macpherson
Director
Director
--
--
Mr. Matthew Pratt Whalen, CPA
Mr. Matthew Pratt Whalen, CPA
Director
Director
--
--
Mr. Alan Weichselbaum
Mr. Alan Weichselbaum
Chief Financial Officer
Chief Financial Officer
--
--
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Erez Aminov
Mr. Erez Aminov
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
1.01M
+3288.20%
Mr. Craig Eagle, M.D.
Mr. Craig Eagle, M.D.
Independent Director
Independent Director
487.81K
--
Dr. Matthew P. Del Giudice
Dr. Matthew P. Del Giudice
Director
Director
--
--
Mr. Ned Macpherson
Mr. Ned Macpherson
Director
Director
--
--
Mr. Matthew Pratt Whalen, CPA
Mr. Matthew Pratt Whalen, CPA
Director
Director
--
--
Mr. Alan Weichselbaum
Mr. Alan Weichselbaum
Chief Financial Officer
Chief Financial Officer
--
--
Umsatzaufteilung
Keine Daten
Keine Daten
Nach Geschäftsbereich
Nach Region
Keine Daten
Aktionärsstatistik
Aktualisiert: Fri, May 16
Aktualisiert: Fri, May 16
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
Bay Shore Trust
22.62%
McNulty (Brian Patrick)
6.31%
The Vanguard Group, Inc.
4.23%
BlackRock Institutional Trust Company, N.A.
3.76%
Aminov (Erez)
3.39%
Other
59.69%
Aktionäre
Aktionäre
Anteil
Bay Shore Trust
22.62%
McNulty (Brian Patrick)
6.31%
The Vanguard Group, Inc.
4.23%
BlackRock Institutional Trust Company, N.A.
3.76%
Aminov (Erez)
3.39%
Other
59.69%
Aktionärstypen
Aktionäre
Anteil
Corporation
22.62%
Individual Investor
11.55%
Investment Advisor
9.09%
Investment Advisor/Hedge Fund
2.98%
Research Firm
0.29%
Pension Fund
0.07%
Bank and Trust
0.07%
Other
53.33%
Institutionelle Beteiligung
Aktualisiert: Tue, Jul 1
Aktualisiert: Tue, Jul 1
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q2
88
13.89M
46.68%
+947.95K
2025Q1
87
13.90M
46.70%
+955.11K
2024Q4
74
13.75M
46.22%
+2.38M
2024Q3
65
14.68M
49.58%
+3.19M
2024Q2
47
12.97M
43.79%
+1.79M
2024Q1
17
12.67M
42.78%
+1.58M
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
Bay Shore Trust
6.73M
22.62%
-89.00K
-1.30%
Dec 31, 2024
McNulty (Brian Patrick)
1.88M
6.31%
-49.00K
-2.54%
Dec 31, 2024
The Vanguard Group, Inc.
1.26M
4.23%
-10.56K
-0.83%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
1.12M
3.76%
+119.04K
+11.91%
Mar 31, 2025
Aminov (Erez)
1.01M
3.39%
+979.88K
+3288.20%
Dec 31, 2024
Eagle (Craig)
487.81K
1.64%
--
--
Dec 31, 2024
Geode Capital Management, L.L.C.
429.25K
1.44%
+15.57K
+3.77%
Mar 31, 2025
Northern Trust Investments, Inc.
151.10K
0.51%
-525.00
-0.35%
Mar 31, 2025
State Street Global Advisors (US)
125.67K
0.42%
+9.88K
+8.53%
Mar 31, 2025
Suncoast Equity Management, LLC.
51.19K
0.17%
--
--
Mar 31, 2025
Mehr Anzeigen
Verbundene ETFs
Aktualisiert: Sat, Aug 2
Aktualisiert: Sat, Aug 2
Name
Anteil
iShares Micro-Cap ETF
0.01%
Proshares Ultra Russell 2000
0%
iShares Russell 2000 Value ETF
0%
iShares Russell 2000 ETF
0%
Global X Russell 2000 ETF
0%
ProShares UltraPro Russell2000
0%
iShares Russell 2000 Growth ETF
0%
ProShares Hedge Replication ETF
0%
iShares Micro-Cap ETF
Anteil0.01%
Proshares Ultra Russell 2000
Anteil0%
iShares Russell 2000 Value ETF
Anteil0%
iShares Russell 2000 ETF
Anteil0%
Global X Russell 2000 ETF
Anteil0%
ProShares UltraPro Russell2000
Anteil0%
iShares Russell 2000 Growth ETF
Anteil0%
ProShares Hedge Replication ETF
Anteil0%
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Art
Verhältnis
Keine Daten
Datum
Art
Verhältnis
Keine Daten
